Price T Rowe Associates Inc Cardiff Oncology, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 49,237 shares of CRDF stock, worth $187,592. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,237
Previous 36,500
34.9%
Holding current value
$187,592
Previous $195,000
43.59%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CRDF
# of Institutions
101Shares Held
12MCall Options Held
823KPut Options Held
78K-
Black Rock Inc. New York, NY2.63MShares$10 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.14MShares$8.14 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA911KShares$3.47 Million0.0% of portfolio
-
State Street Corp Boston, MA805KShares$3.07 Million0.0% of portfolio
-
Mai Capital Management663KShares$2.53 Million0.02% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $165M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...